Figure 2.

Activation of STING in vivo inhibits tumor metastasis

(A) MC38-luciferase cells were injected to construct a transfer model and treated with DMXAA (i.p.) (10 mg/kg/3 days) or PBS (i.p.) for 3 weeks. Bioluminescence signal imaging of representative mice (left) and quantitation analyses of bioluminescence (right) were done following treatments,n ≥ 5.

(B) Survival curves of liver metastatic mouse model after DMXAA and PBS treatment compared to the non-operated group (mock).

(C) Representative macroscopic photograph of livers of the control model (top panel) and DMXAA (10 mg/kg/3 days)-treated mice (lower panel) with metastatic cancer nodules.

(D) H&E staining of liver from control and DMXAA-treated liver metastasis mouse model.

(E) Levels of ALT and AST in peripheral blood of mice after 3 weeks of DMXAA or PBS treatment.

(F) Western blot to detect the protein levels of STING, TBK1, p-TBK1, IRF3, and p-IRF3 in mouse liver using GAPDH as the loading control.

(G) Flow cytometric analysis of M1 (CD11c⁺) and M2(CD206⁺) ratios in F4/80⁺/CD11b⁺ macrophage populations isolated from liver metastases.